Merus (MRUS) Projected to Post Earnings on Wednesday

Merus (NASDAQ:MRUS) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.89) per share and revenue of $10.57 million for the quarter.

Merus Trading Down 0.5 %

NASDAQ MRUS opened at $47.37 on Monday. The stock has a market capitalization of $3.24 billion, a price-to-earnings ratio of -11.99 and a beta of 1.11. The stock has a 50-day moving average of $41.72 and a 200 day moving average of $46.91. Merus has a twelve month low of $37.77 and a twelve month high of $61.61.

Analyst Upgrades and Downgrades

MRUS has been the subject of several research analyst reports. Citigroup upped their target price on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 price objective on shares of Merus in a report on Monday, December 9th. Wells Fargo & Company assumed coverage on shares of Merus in a research note on Friday, February 7th. They set an “overweight” rating and a $91.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price target on shares of Merus in a research note on Monday, December 2nd. Finally, The Goldman Sachs Group began coverage on Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Merus currently has a consensus rating of “Buy” and an average target price of $85.92.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.